🔴 Natera is trading 5% down today as biotech lags broader indexes

Natera is trading at $404.91, down 4.87%, amid biotech-sector pressure; no specific catalyst directly explaining the decline was found.

• The sector ETF fell 2.50% during the regular session, while major U.S. indexes were higher.
• Natera’s AFT-70 NAVIGATE Phase III trial announcement with Alliance Foundation Trials and Genentech was positive company news, not an evident explanation for the decline.